Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 55
Filter
4.
An. bras. dermatol ; 95(supl.1): 19-38, Nov.-Dec. 2020. tab, graf
Article in English | LILACS | ID: biblio-1152780

ABSTRACT

Abstract Background: Isotretinoin is a synthetic retinoid, derived from vitamin A, with multiple mechanisms of action and highly effective in the treatment of acne, despite common adverse events, manageable and dose-dependent. Dose-independent teratogenicity is the most serious. Therefore, off-label prescriptions require strict criteria. Objective: To communicate the experience and recommendation of Brazilian dermatologists on oral use of the drug in dermatology. Methods: Eight experts from five universities were appointed by the Brazilian Society of Dermatology to develop a consensus on indications for this drug. Through the adapted DELPHI methodology, relevant elements were listed and an extensive analysis of the literature was carried out. The consensus was defined with the approval of at least 70% of the experts. Results: With 100% approval from the authors, there was no doubt about the efficacy of oral isotretinoin in the treatment of acne, including as an adjunct in the correction of scars. Common and manageable common adverse events are mucocutaneous in nature. Others, such as growth retardation, abnormal healing, depression, and inflammatory bowel disease have been thoroughly investigated, and there is no evidence of a causal association; they are rare, individual, and should not contraindicate the use of the drug. Regarding unapproved indications, it may represent an option in cases of refractory rosacea, severe seborrheic dermatitis, stabilization of field cancerization with advanced photoaging and, although incipient, frontal fibrosing alopecia. For keratinization disorders, acitretin performs better. In the opinion of the authors, indications for purely esthetic purposes or oil control are not recommended, particularly for women of childbearing age. Conclusions: Approved and non-approved indications, efficacy and adverse effects of oral isotretinoin in dermatology were presented and critically evaluated.


Subject(s)
Humans , Female , Acne Vulgaris/drug therapy , Dermatologic Agents/adverse effects , Dermatology , Brazil , Isotretinoin/therapeutic use , Administration, Oral , Consensus
6.
An. bras. dermatol ; 95(2): 150-157, Mar.-Apr. 2020. tab
Article in English | ColecionaSUS, LILACS, ColecionaSUS | ID: biblio-1130840

ABSTRACT

Abstract Background: Psoriasis is associated with atherosclerosis and increased cardiovascular risk. Currently, an automated ultrasound, called quantitative intima media thickness, has proven to be a useful method to evaluate subclinical atherosclerosis. Objectives: To compare increased cardiovascular risk in psoriasis patients receiving two types of treatments: Methotrexate and tumor necrosis factor inhibitor and to evaluate the correlation between the Framingham score and quantitative intima media thickness. Methods: Fifty patients with plaque psoriasis were selected from June 2017 to July 2018, divided into two groups, receiving methotrexate and tumor necrosis factor inhibitor. Measurement of abdominal circumference, blood pressure, body mass index and presence of metabolic syndrome were performed. Afterwards, the patients were evaluated for increased cardiovascular risk with the Framingham score and for the quantitative intima media thickness of the carotid arteries. Results: The mean age was 54.8 (±12.5) with a slight male predominance (58%). Overall, 84% of the patients had elevated waist circumference, 82% had a body mass index above ideal, and 50% had a metabolic syndrome. For the correlation between quantitative intima media thickness and Framingham Score, Pearson's linear correlation coefficient was 0.617 (p < 0.001), indicating a moderate to strong positive association. Study limitations: The protective effect of the therapies cited in relation to the increased cardiovascular risk was not evaluated. Conclusions: A moderate to strong positive association was found correlating the Framingham Score values with the quantitative intima media thickness measurement and it is not possible to state which drug has the highest increased cardiovascular risk.


Subject(s)
Humans , Male , Female , Adult , Aged , Psoriasis/complications , Psoriasis/drug therapy , Cardiovascular Diseases/chemically induced , Methotrexate/adverse effects , Dermatologic Agents/adverse effects , Carotid Intima-Media Thickness , Tumor Necrosis Factor Inhibitors/adverse effects , Psoriasis/epidemiology , Reference Values , Severity of Illness Index , Brazil/epidemiology , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/diagnostic imaging , Body Mass Index , Comorbidity , Cross-Sectional Studies , Risk Factors , Risk Assessment , Waist Circumference , Middle Aged
7.
Braz. j. otorhinolaryngol. (Impr.) ; 86(1): 99-104, Jan.-Feb. 2020. tab
Article in English | LILACS | ID: biblio-1089377

ABSTRACT

Abstract Introduction Isotretinoin (13 cis-retinoic acid) is the most effective treatment for acne vulgaris and is the only treatment option that can provide either remission or a permanent cure. Objective The aim of this study was to use both subjective and objective methods to assess the nasal complaints of patients with severe acne who received oral isotretinoin therapy. Methods Fifty-four subjects were enrolled in the study. All the subjects were assessed with subjective (NOSE and VAS questionnaires) and objective (rhinomanometry and saccharine) tests to determine the severity of their nasal complaints. Results The mean severity scores (min: 0; max: 100) for nasal dryness/crusting and epistaxis were 0.47 ± 1.48 (0-5); 0.35 ± 1.30 (0-5) at admission, 3.57 ± 4.45 (0-10); 2.26 ± 4.71 (0-20) at the first month, and 4.28 ± 6 (0-20); 2.26 ± 4.71 (0-20) at the third month of the treatment respectively. Total nasal resistance of 0.195 ± 0.079 (0.12-0.56) Pa/cm3/s at admission, 0.21 ± 0.084 (0.12-0.54) Pa/cm3/s at the first month, and 0.216 ± 0.081 (0.14-0.54) Pa/cm3/s at the third month. Conclusion Oral isotretinoin therapy can cause the complaint of nasal obstruction. In addition, nasal complaints, such as dryness/crusting and epistaxis, significantly increase in patients during the therapy schedule.


Resumo Introdução A isotretinoína (ácido-13 cis-retinóico) é o tratamento por via oral mais eficaz para acne vulgar e é a única opção de tratamento que pode produzir remissão ou cura permanente. Objetivo Usar métodos subjetivos e objetivos para avaliar as queixas nasais de pacientes com acne grave que receberam terapia com isotretinoína oral. Método Foram incluídos no estudo 54 indivíduos. Todos os indivíduos foram avaliados por meio de testes subjetivos (questionários NOSE e escala EVA) e objetivos (rinomanometria e teste de sacarina) para determinar a gravidade de suas queixas nasais. Resultados Os escores médios de gravidade (min: 0; max: 100) para ressecamento/crostas e epistaxe nasal foram de 0,47 ± 1,48 (0-5); 0,35 ± 1,30 (0-5) no início, 3,57 ± 4,45 (0-10); 2,26 ± 4,71 (0-20) no primeiro mês e 4,28 ± 6 (0-20); 2,26 ± 4,71 (0-20) no terceiro mês do tratamento, respectivamente. A resistência nasal total foi de 0,195 ± 0,079 (0,12 a 0,56) Pa/cm3/s no início, 0,21 ± 0,084 (0,12 a 0,54) Pa/cm3/s no primeiro mês e 0,216 ± 0,081 (0,14 a 0,54) Pa/cm3/s no terceiro mês. Conclusão A terapia com isotretinoína por via oral pode resultar em queixa de obstrução nasal. Além disso, queixas nasais, tais como ressecamento/formação de crostas e epistaxe, aumentam significativamente nos pacientes durante o esquema terapêutico.


Subject(s)
Humans , Adolescent , Adult , Young Adult , Isotretinoin/pharmacology , Dermatologic Agents/pharmacology , Nasal Cavity/drug effects , Saccharin , Sweetening Agents , Severity of Illness Index , Isotretinoin/adverse effects , Isotretinoin/therapeutic use , Nasal Obstruction/diagnosis , Nasal Obstruction/etiology , Epistaxis/etiology , Prospective Studies , Surveys and Questionnaires , Acne Vulgaris/drug therapy , Rhinomanometry , Dermatologic Agents/adverse effects , Dermatologic Agents/therapeutic use , Symptom Assessment
8.
Rev. Assoc. Med. Bras. (1992) ; 65(4): 530-534, Apr. 2019.
Article in English | LILACS | ID: biblio-1003055

ABSTRACT

The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field in order to standardize producers to assist the reasoning and decision-making of doctors. The information provided through this project must be assessed and criticized by the physician responsible for the conduct that will be adopted, depending on the conditions and the clinical status of each patient.


Subject(s)
Humans , Psoriasis/drug therapy , Dermatologic Agents/administration & dosage , Immunosuppressive Agents/administration & dosage , Antibodies, Monoclonal/administration & dosage , Psoriasis/pathology , Time Factors , Severity of Illness Index , Brazil , Methotrexate/administration & dosage , Methotrexate/adverse effects , Treatment Outcome , Cyclosporine/administration & dosage , Cyclosporine/adverse effects , Acitretin/administration & dosage , Acitretin/adverse effects , Dermatologic Agents/adverse effects , Clinical Decision-Making , Immunosuppressive Agents/adverse effects , Antibodies, Monoclonal/adverse effects
10.
Medwave ; 18(2): e7173, 2018.
Article in English, Spanish | LILACS | ID: biblio-912143

ABSTRACT

INTRODUCCIÓN: La artritis psoriásica es una artritis inflamatoria sin una clara etiología, con el tratamiento biológico como un pilar fundamental en pacientes más complejos. Existen varias alternativas para tratamiento biológico, debido a su alto costo, es importante evaluar la real efectividad de estos para un buen tratamiento. MÉTODOS: Para responder esta pregunta utilizamos Epistemonikos, la mayor base de datos de revisiones sistemáticas en salud a nivel mundial, la cual es mantenida mediante búsquedas en múltiples fuentes de información, incluyendo MEDLINE, EMBASE, Cochrane, entre otras. Extrajimos los datos desde las revisiones identificadas, reanalizamos los datos de los estudios primarios, realizamos un metanálisis y preparamos una tabla de resumen de los resultados utilizando el método GRADE. RESULTADOS Y CONCLUSIONES: Identificamos 12 revisiones sistemáticas que en conjunto incluyen tres ensayos aleatorizados. Concluimos que el ustekinumab logra una mejoría clínica en pacientes con psoriasis, y probablemente no se asocia a efectos adversos graves.


INTRODUCTION: Psoriatic arthritis is an inflammatory arthritis without a clear etiology. Biological therapy is key for its treatment, especially in more complex patients. There are several alternatives for biological treatment, but due to its high cost, it is important to evaluate their real effectiveness. METHODS: To answer this question we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach. RESULTS AND CONCLUSIONS: We identified 12 systematic reviews including three randomized trials overall. We concluded ustekinumab leads to clinical improvement in psoriatic arthritis, and probably is not associated to severe adverse effects.


Subject(s)
Humans , Arthritis, Psoriatic/drug therapy , Dermatologic Agents/therapeutic use , Ustekinumab/therapeutic use , Arthritis, Psoriatic/physiopathology , Randomized Controlled Trials as Topic , Databases, Factual , Treatment Outcome , Dermatologic Agents/adverse effects , Ustekinumab/adverse effects
11.
Medwave ; 18(7): e7363, 2018.
Article in English, Spanish | LILACS | ID: biblio-966478

ABSTRACT

INTRODUCCIÓN: Los tratamientos biológicos han aparecido como principal alternativa para el manejo de los pacientes con psoriasis en placa que no responden a tratamiento convencional, resultando necesario evaluar su real efectividad y seguridad. MÉTODOS: Realizamos una búsqueda en Epistemonikos, la mayor base de datos de revisiones sistemáticas en salud, la cual es mantenida mediante el cribado de múltiples fuentes de información, incluyendo MEDLINE, EMBASE, Cochrane, entre otras. Extrajimos los datos desde las revisiones identificadas, analizamos los datos de los estudios primarios, realizamos un metanálisis y preparamos una tabla de resumen de los resultados utilizando el método GRADE. RESULTADOS Y CONCLUSIONES: Identificamos 21 revisiones sistemáticas que en conjunto incluyeron diez estudios primarios, todos correspondientes a ensayos aleatorizados. Concluimos que secukinumab logra mejoría clínica en pacientes con psoriasis en placa, aunque probablemente se asocia a efectos adversos graves.


INTRODUCTION: Biological treatments have appeared as the main alternative for the management of patients with plaque psoriasis that do not respond to conventional treatment. So, evaluating its actual efficacy and safety is needed. METHODS: We searched in Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach. RESULTS AND CONCLUSIONS: We identified 21 systematic reviews including ten studies overall, of which all were randomized trials. We concluded secukinumab achieves clinical improvement in patients with plaque psoriasis, although it is probably associated with serious adverse effects.


Subject(s)
Humans , Psoriasis/drug therapy , Dermatologic Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Psoriasis/pathology , Randomized Controlled Trials as Topic , Databases, Factual , Treatment Outcome , Dermatologic Agents/adverse effects , Antibodies, Monoclonal, Humanized , Antibodies, Monoclonal/adverse effects
13.
An. bras. dermatol ; 92(3): 401-403, May-June 2017. graf
Article in English | LILACS | ID: biblio-886977

ABSTRACT

Abstract Methotrexate has immunosuppressive effects and is administered for refractory chronic urticaria. We present a case of Pneumocystis jirovecii pneumonia in a patient with refractory chronic urticaria managed by low-dose weekly methotrexate treatment (total cumulative dose 195mg). Our study highlights the importance of providing prompt diagnosis and treatment of Pneumocystis jirovecii pneumonia in patients with chronic urticaria under methotrexate therapy.


Subject(s)
Humans , Female , Adult , Pneumonia, Pneumocystis/chemically induced , Methotrexate/adverse effects , Pneumocystis carinii , Dermatologic Agents/adverse effects , Pneumonia, Pneumocystis/diagnostic imaging , Urticaria/drug therapy , Tomography, X-Ray Computed , Methotrexate/administration & dosage , Chronic Disease , Dermatologic Agents/administration & dosage
15.
An. bras. dermatol ; 91(6): 820-821, Nov.-Dec. 2016. graf
Article in English | LILACS | ID: biblio-837973

ABSTRACT

Abstract Isotretinoin has been considered a unique drug for acne treatment. However, it is associated with numerous adverse effects. Isotretinoin can trigger premature ventricular contractions. This report describes a 33-year-old-woman who presented with palpitations for 1 week while undergoing 1-month isotretinoin treatment for mild-moderate facial acne. An electrocardiogram and Holter monitoring showed premature ventricular contractions during isotretinoin (Roaccutane, Roche) treatment. Isotretinoin-related premature ventricular contractions were strongly suggested in this case due to the existence of documented premature ventricular contractions on electrocardiograms and the disappearance of these premature ventricular contractions two weeks after termination of the treatment To the authors' knowledge, there has been 1 reported case of premature ventricular contractions linked to isotretinoin use; this report describes a second such case.


Subject(s)
Humans , Female , Adult , Isotretinoin/adverse effects , Ventricular Premature Complexes/chemically induced , Dermatologic Agents/adverse effects , Time Factors , Acne Vulgaris/drug therapy , Ventricular Premature Complexes/physiopathology , Electrocardiography
16.
An. bras. dermatol ; 90(3,supl.1): 43-45, May-June 2015. ilus
Article in English | LILACS | ID: lil-755762

ABSTRACT

Abstract

Methotrexate has been widely used for many years in the treatment of a variety of diseases. Acute pneumonitis and bone marrow suppression are very serious side effects in methotrexate treatment. A 48-year-old man with end-stage renal disease undergoing chronic hemodialysis developed combined acute pneumonitis and pancytopenia after a cumulative dose of 20 mg methotrexate for bullous pemphigoid. Continuous renal replacement therapy (CRRT) can effi ciently decrease serum methotrexate concentration. A rapid improvement of clinical symptoms and resolution of pulmonary opacifi cation were found after CRRT. Blood cell counts returned to normal after component blood transfusion and cytokine supportive therapy. Patients with impaired renal function are at high risk of methotrexate toxicity, and low-dose methotrexate should be prescribed with great caution.

.


Subject(s)
Humans , Male , Middle Aged , Dermatologic Agents/adverse effects , Lung Diseases, Interstitial/chemically induced , Methotrexate/adverse effects , Pancytopenia/chemically induced , Pemphigoid, Bullous/drug therapy , Dermatologic Agents/administration & dosage , Kidney Failure, Chronic/therapy , Lung Diseases, Interstitial/therapy , Methotrexate/administration & dosage , Pancytopenia/therapy , Renal Dialysis , Risk Factors , Treatment Outcome
17.
An. bras. dermatol ; 90(3): 367-375, May-Jun/2015. tab
Article in English | LILACS | ID: lil-749653

ABSTRACT

Abstract Psoriasis is a chronic inflammatory disease that affects primarily the skin and joints, with a worldwide incidence of 2-3%. Fifty percent of patients are women, most still diagnosed during childbearing years. Currently,the estimate is that up to 107 thousand deliveries are performed annually in women with psoriasis, a percentage of them in women with moderate to severe disease. Fetal risks in pregnant women with psoriasis derive both from maternal disease and the medications used to control the illness. The purpose of this review is to study the effect of the main drugs used in the treatment of psoriasis and psoriatic arthritis during pregnancy and lactation, with particular focus on disease-modifying anti-rheumatic biological drugs, biological therapies, immunobiologics or biologics.


Subject(s)
Female , Humans , Pregnancy , Arthritis, Psoriatic/drug therapy , Breast Feeding , Dermatologic Agents/adverse effects , Lactation , Pregnancy Complications/drug therapy , Psoriasis/drug therapy , Anti-Inflammatory Agents/adverse effects , Antirheumatic Agents/adverse effects , Immunologic Factors/adverse effects , Risk Factors , Tumor Necrosis Factor-alpha/antagonists & inhibitors
18.
An. bras. dermatol ; 89(6): 1017-1018, Nov-Dec/2014.
Article in English | LILACS | ID: lil-727640

ABSTRACT

Immunobiologic therapy is indicated for severe forms of psoriasis, resistant to conventional therapy. There is growing concern about their safety profile and possible association with cancer development. This article documents two cases of renal cell cancer during treatment with biologic therapy, reviewing what is described in the literature . The risk of solid tumors as a complication of using TNF-alpha inhibitors is controversial. No conclusion can be drawn from the data in the literature, however, we believe that special attention should be given to those with known risk factors for a specific neoplasm.


Subject(s)
Adult , Aged , Humans , Male , Middle Aged , Carcinoma, Renal Cell/chemically induced , Immunologic Factors/adverse effects , Kidney Neoplasms/chemically induced , Psoriasis/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Antibodies, Monoclonal/adverse effects , Dermatologic Agents/adverse effects , Immunoglobulin G/adverse effects , Receptors, Tumor Necrosis Factor , Risk Factors , Treatment Outcome
19.
An. bras. dermatol ; 89(4): 657-659, Jul-Aug/2014. graf
Article in English | LILACS | ID: lil-715542

ABSTRACT

Acne fulminans is a rare and serious condition characterized by the sudden onset of nodular and ulcerative acne lesions associated with systemic symptoms. It has been recognized a subset of patients with a sudden worsening of acne, often during treatment with oral isotretinoin, but without the strong presence of systemic involvement. Recognized by some authors as "pseudo-acne fulminans" or " acne fulminans sine fulminans," we report a case with these features in order to draw attention to the recognition and early management of this manifestation.


Subject(s)
Adolescent , Humans , Male , Acne Vulgaris/drug therapy , Dermatologic Agents/administration & dosage , Isotretinoin/administration & dosage , Acne Vulgaris/chemically induced , Dermatologic Agents/adverse effects , Glucocorticoids/administration & dosage , Isotretinoin/adverse effects , Prednisone/administration & dosage , Skin Ulcer/drug therapy , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL